View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Catalent
2 October 2019

Catalent to Discuss how Drug Design Influences Patient Outcomes at PODD

Catalent, a leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies and consumer health products, announced it will present at the 9th Partnership Opportunities in Drug Delivery (PODD) annual conference at the Renaissance Boston Waterfront Hotel, Boston on 7-8 October 2019.

On 8 October at 1:20pm, Cornell Stamoran, PhD, Founder and Co-Chair of the Catalent Applied Drug Delivery Institute, will moderate the “Smart Drug Design and Development – from Candidate to Phase 1” panel during the “Formulations” breakout session.

The panel will bring together scientists from industry and academia including Sudhakar Garad, PhD, Global Head of Pharmaceutical and Chemical Profiling, Novartis Institutes for Biomedical Research, Keith Horspool, VP of External Alternative CMC Development, Rebecca Carrier PhD, Professor, Chemical Engineering, Northeastern University and others.

The panellists will explore the key considerations for transitioning a molecule from discovery to clinic and will discuss how every design decision made during this process has the potential to influence patient outcomes.

Dr Stamoran leads Catalent’s strategic planning, market intelligence and government affairs efforts. He has spent nearly 30 years in advanced drug and biologics delivery and outsourcing. Dr Stamoran founded the Catalent Applied Drug Delivery Institute in 2012 to serve as a link between industry and academia, advance education and training in drug delivery in academia and the industry, accelerate adoption of applied drug delivery technologies to develop better treatments, and foster industry collaboration on major issues pertaining to drug development, formulation and delivery.

Catalent utilised two technologies targeting duodenal and sublingual biological barriers through a parallel screening approach to assess the oral delivery potential of Salmon Calcitonin.
Catalent Pharma provided London-based pharmaceutical company Trio Medicines with three formulation technologies and four prototypes showing improved solubility and bioavailability for an acetyl prodrug of...
With Catalent's team of packaging experts and extensive cold chain capabilities, this case study discusses the creation of a custom packaging and distribution solution to...
The number of clinical trials in the Asia-Pacific (APAC) region is growing as sponsors tap into expanding pharmaceutical market.
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology